Skip to Content
Print Share

Generic Mycamine Availability

Mycamine is a brand name of micafungin, approved by the FDA in the following formulation(s):

MYCAMINE (micafungin sodium - injectable;iv (infusion))

  • Manufacturer: ASTELLAS
    Approval date: March 16, 2005
    Strength(s): EQ 50MG BASE/VIAL [RLD]
  • Manufacturer: ASTELLAS
    Approval date: June 27, 2006
    Strength(s): EQ 100MG BASE/VIAL [RLD]

Has a generic version of Mycamine been approved?

No. There is currently no therapeutically equivalent version of Mycamine available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mycamine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Cyclic hexapeptides having antibiotic activity
    Patent 6,107,458
    Issued: August 22, 2000
    Inventor(s): Ohki; Hidenori & Tomishima; Masaki & Yamada; Akira & Takasugi; Hisashi
    Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
    This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
    Patent expiration dates:
    • March 16, 2019
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 16, 2019
      ✓ 
      Patent use: TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Stabilized pharmaceutical composition in lyophilized form
    Patent 6,774,104
    Issued: August 10, 2004
    Inventor(s): Seiji; Sawai & Akihiro; Kasai & Kazumi; Otomo
    Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
    A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
    Patent expiration dates:
    • January 8, 2021
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
      ✓ 
      Drug product
    • January 8, 2021
      ✓ 
      Patent use: TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
      ✓ 
      Drug product
Add to My Med List

More about Mycamine (micafungin)

Consumer resources

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide